Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Aribio Co. Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed among 3 distinct examiners and 3 distinct art units. This means each pending action is being reviewed by a different examiner in a different art unit, showing a lack of concentration at both levels.
MOU, LIYUAN is the busiest examiner for the company, with 1 pending office action. This distribution shows that no single examiner or art unit has a dominant influence over the company's current pending matters. Because each of the 3 actions is in a different art unit, the company must manage its prosecution strategy across three separate technical groups at the patent office. The distribution of 3 actions across 3 examiners and 3 art units requires a flexible approach to address the varying requirements of different specialized reviewers within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 55d |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | BORALSKY, LUKE ALAN | 83d |
| 19003405 | COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1628 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 1693 | §102§103Other | Non-Final OA | 55d | Pending | Dec 27, 2024 |
| 19003405 | COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | MOU, LIYUAN | 1628 | §103DP | Non-Final OA | — | Pending | Dec 27, 2024 |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | 83d | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial